RT Journal Article SR Electronic(1) A1 Hospenthal, D. A1 Gretzinger, K. A1 Rogers, A.YR 1989 T1 Treatment of a murine model of systemic candidiasis with liposomal amphotericin B bearing antibody to Candida albicans JF Journal of Medical Microbiology, VO 30 IS 3 SP 193 OP 197 DO https://doi.org/10.1099/00222615-30-3-193 PB Microbiology Society, SN 1473-5644, AB Survival of mice infected with an intravenous injection of Candida albicans was observed in a short-term (21-day) survival study. Concentration of C. albicans in the kidneys, liver, and spleen was determined at various times. The effects of treatment with the commercial formulation of amphotericin B (fAMB), liposomal amphotericin B (LAMB), and liposomal amphotericin B bearing external antibody specific for C. albicans (LAMB-Ab) were compared. In single intravenous treatment dosages of 0.6 mg of amphotericin B/kg, the liposomal forms of the drug (LAMB and LAMB-Ab) enhanced the percentage survival and mean survival time of mice in comparison with those treated with the unencapsulated antifungal compound, fAMB (p <0.03 and p<0.001, respectively). LAMB-Ab, at this dosage, produced an increase in the survival (p<0.007) of mice over that produced by LAMB. LAMB-Ab treatment caused a greater than 3-fold increase over fAMB. The percentage of LAMB-Ab-treated mice which survived for 21 days was almost double that of the LAMB-treated mice. The increase in survival following this treatment did not, however, lead to the eradication of C. albicans in all mice which survived to the end of the experiment., UL https://www.microbiologyresearch.org/content/journal/jmm/10.1099/00222615-30-3-193